Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065923 | 1.00 | TAAR1 (0.47) | TAAR1CYP2C19CYP1A2CYP2C9KIF11 | |
| SCHEMBL2065906 | 1.00 | TAAR1 (0.47) | TAAR1CYP2C19CYP1A2CYP2C9KIF11 | |
| SCHEMBL7671955 | 0.89 | TAAR1 (0.44) | TAAR1CYP2C19CYP1A2CYP2C9KIF11 | |
| SCHEMBL9194705 | 0.87 | CYP2C19 (0.52) | CYP2C19CYP1A2CYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL11522604 | 0.87 | SIGMAR1 (0.42) | TAAR1CYP2C19CYP1A2CYP2C9KIF11 | |
| SCHEMBL15976484 | 0.85 | SCN5A (0.43) | TAAR1CYP2C19CYP1A2CYP2C9KIF11 | |
| Alcohol SCHEMBL1532264 | 0.85 | TAAR1 (0.44) | TAAR1CYP2C19CYP1A2CYP2C9KIF11 | |
| SCHEMBL23014014 | 0.83 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL1292634 | 0.83 | TAAR1 (0.50) | TAAR1CYP2C19CYP1A2CYP2C9KIF11 | |
| SCHEMBL10505123 | 0.83 | CYP1A2 (0.56) | TAAR1CYP2C19CYP1A2CYP2C9KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107921297-A | Antiperspirant agent | 拜尔斯道夫股份有限公司 | 2018-04-17 | — | — | CN | claimed |
| CN-107847769-A | Antiperspirant agent | 拜尔斯道夫股份有限公司 | 2018-03-27 | — | — | CN | claimed |
| CN-107847770-A | Antiperspirant agent | 拜尔斯道夫股份有限公司 | 2018-03-27 | — | — | CN | claimed |
| CN-107847404-A | Cosmetic preparation for reducing perspiration | 拜尔斯道夫股份有限公司 | 2018-03-27 | — | — | CN | claimed |
| CN-107847771-A | Antiperspirant agent | 拜尔斯道夫股份有限公司 | 2018-03-27 | — | — | CN | claimed |
| CN-107847403-A | Cosmetic preparation for reducing perspiration | 拜尔斯道夫股份有限公司 | 2018-03-27 | — | — | CN | claimed |
| CN-108472211-A | Method for reducing perspiration | 拜尔斯道夫股份有限公司 | 2018-08-31 | — | — | CN | disclosed |
| CN-107921297-A | Antiperspirant agent | 拜尔斯道夫股份有限公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107847769-A | Antiperspirant agent | 拜尔斯道夫股份有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107847770-A | Antiperspirant agent | 拜尔斯道夫股份有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107847404-A | Cosmetic preparation for reducing perspiration | 拜尔斯道夫股份有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107847771-A | Antiperspirant agent | 拜尔斯道夫股份有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107847403-A | Cosmetic preparation for reducing perspiration | 拜尔斯道夫股份有限公司 | 2018-03-27 | — | — | CN | disclosed |
| US-6624175-B2 | 4-heterocyclic substituted quinoline derivative treats disorderes associated with pathogenic neurokinin-3 receptor, such as anxiety, depression, schizophrenia, obesity, chronic pulmonary obstructive disorder or pain | NEUROGEN CORPORATION | 2003-09-23 | — | — | US | disclosed |
| EP-1165542-B1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2003-08-20 | — | — | EP | disclosed |
| US-20020198232-A1 | 4-substituted quinoline derivatives | NEUROGEN CORPORATION (US) | 2002-12-26 | — | — | US | disclosed |
| WO-2000058303-A9 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6413982-B1 | 5-ETHYL-5-PHENYL-2-(3-METHOXY-2-PHENYLQUINOLIN-4-YL)-IMIDAZO -LINE; CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISEASES AND DISORDERS; BINDS WITH HIGH AFFINITY TO NEUROKININ-3 (NK-3) AND/OR GAMMA-AMINOBUTYRIC ACID RECEPTORS; SYNERGISTIC | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | disclosed |
| EP-1165542-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058303-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198232-A1 | 4-substituted quinoline derivatives | GABRA3, GABRB3, GABRR3 | TAAR1 267/4885CYP2C19 707/4885CYP1A2 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.